Warp Speed’s $2.1B commitment to Sanofi-GSK COVID-19 program brings total to $8.3B across seven vaccines

A preclinical vaccine from Sanofi and GSK may be months behind other COVID-19 vaccines in development, but the U.S. government has made its largest financial commitment yet to its development and manufacturing, pledging up to $2.1 billion as part of Operation Warp Speed.

That brings the U.S. government’s total commitment to about $8.3 billion across seven vaccine programs that use four different modalities, most of which are already in the clinic (see “COVID-19 Vaccines with U.S. Government Funding”). ...